Adequan is considered one of the safer medications available for treating osteoarthritis in dogs. It is FDA-approved, and clinical trials showed very few adverse reactions, with most being mild and temporary. That said, it does carry specific risks for dogs with bleeding disorders or certain organ problems, so it’s not appropriate for every dog.
What Adequan Does in the Joint
Adequan is an injectable form of polysulfated glycosaminoglycan (PSGAG), classified as a disease-modifying osteoarthritis drug. Unlike pain medications that simply mask symptoms, Adequan works inside the joint itself. It inhibits enzymes that break down cartilage while also stimulating the production of hyaluronic acid, proteoglycans, and collagen, all key building blocks of healthy joint tissue. The net effect is that it slows cartilage destruction and supports the joint’s ability to repair itself, rather than just reducing inflammation.
Side Effects From Clinical Trials
The FDA approval data for Adequan Canine paints a reassuring picture. In the clinical trials, the only adverse reactions recorded were one case of transient injection site pain, two cases of transient diarrhea, and one incident of preputial bleeding that the investigating veterinarian did not believe was related to the treatment. In safety testing at higher doses (50 mg/kg, well above the standard therapeutic dose), transient injection site pain was noted in a small number of dogs but resolved on its own.
These numbers make Adequan notably well-tolerated compared to many other arthritis treatments. Oral anti-inflammatory drugs, by contrast, commonly cause gastrointestinal upset, and long-term use can stress the liver or kidneys. Adequan doesn’t carry those same organ-related risks for most dogs.
The Bleeding Risk Worth Knowing About
The most important safety concern with Adequan is its effect on blood clotting. PSGAG is structurally similar to heparin, a blood-thinning compound. At therapeutic doses this effect is minimal, but it is dose-related, meaning higher amounts increase the risk. Because of this heparin-like property, Adequan is contraindicated in dogs with known or suspected bleeding disorders. If your dog has a clotting condition like von Willebrand disease, or is scheduled for surgery, this is critical information to share with your vet.
Dogs Who Shouldn’t Receive Adequan
Beyond bleeding disorders, there are a few other situations where Adequan requires extra caution or should be avoided entirely:
- Hypersensitivity to PSGAG. Dogs that have had an allergic reaction to the drug should not receive it again.
- Kidney or liver impairment. The product label advises using Adequan with caution in dogs with renal or hepatic problems.
- Breeding, pregnant, or lactating dogs. Safety has not been evaluated in these groups, so there is no data confirming it’s safe during reproduction or nursing.
How It’s Given
Adequan is administered as an intramuscular injection at a dose of 2 mg per pound of body weight. The standard protocol is twice weekly for up to four weeks, totaling a maximum of eight injections in that initial course. Many veterinarians teach owners to give the injections at home, which makes the schedule more manageable. The treatment course can be repeated when signs of arthritis return.
In practice, many vets prescribe Adequan on a longer-term maintenance schedule, such as monthly injections after the initial loading phase. This goes beyond the FDA-approved label, but it’s a widely accepted approach in veterinary medicine. Your vet will tailor the frequency based on how your dog responds.
Drug Interactions
There are no known drug interactions with Adequan, and it is commonly used alongside other arthritis treatments. Dogs receiving anti-inflammatory pain relievers, joint supplements, or other therapies can typically continue those while on Adequan. This flexibility is one reason veterinarians often include it as part of a multimodal pain management plan rather than a standalone treatment.
Long-Term Use
The FDA-approved protocol covers only the initial four-week course, and formal long-term safety studies for extended or repeated use haven’t been published. However, Adequan has been in veterinary use for decades, and many dogs receive repeated courses or ongoing maintenance injections over months or years. The veterinary community generally considers this safe based on cumulative clinical experience, though there is no large-scale trial data to point to for multi-year use. Because of this, some vets may recommend periodic bloodwork, particularly for dogs with preexisting health concerns, to monitor liver and kidney function over time.
For most dogs with osteoarthritis, Adequan carries a favorable safety profile, especially when weighed against the gastrointestinal and organ risks of long-term anti-inflammatory use. The dogs most likely to have problems are those with undiagnosed bleeding disorders or significant liver and kidney disease, which is why a baseline health assessment before starting treatment makes sense.